Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RLMDthis companyRelmada Therapeutics, Inc.	$4.12	-3.33×	2.2×	0×	-3.26×	-98.7%	0.0%	0.0%	0.0%	-66.3%	-67.5%	-24.0%	0×	0.06×	0×	14.62×	0.0%	2	13.25	1	C-
ACETAdicet Bio, Inc.	$3.11	-0.5×	0.36×	0×	-0.31×	-8.6%	0.0%	0.0%	0.0%	-73.4%	-70.2%	-167.1%	0.09×	0.22×	-3,392.06×	7.47×	0.0%	1	-6.93	3	B-
ACRVAcrivon Therapeutics, Inc. Common Stock	$1.64	-1.19×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.02×	0.51×	0×	7.69×	0.0%	1	-2.78	3	B-
CBUSCibus, Inc.	$1.25	-0.63×	3.65×	21.88×	-3.72×	-625.8%	-62.8%	-1853.9%	-3492.3%	-582.2%	-23.2%	-64.3%	12.28×	-2.84×	-1.9×	0.72×	0.0%	3	-4.45	1	D+
FBIOFortress Biotech, Inc.	$1.96	-54.3×	2.05×	1.61×	-4.81×	-588.7%	66.9%	-111.0%	10.8%	13.7%	-50.0%	-64.4%	1.49×	0.25×	-8.06×	2.49×	0.7%	6	0.11	4	A
IMUXImmunic, Inc.	$8.02	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
Peer median	—	-0.86×	0.82×	0×	-0.71×	-91.8%	0.0%	0.0%	0.0%	-69.2%	-50.0%	-70.4%	0.09×	0.22×	-1.9×	2.49×	0.0%	2	-4.45	3	—